Gene Therapy Shows Promise for Aggressive Lymphoma
By webmd.com
An experimental gene therapy for aggressive non-Hodgkin lymphoma beat back more than a third of cancers that seemed untreatable, the therapy's developers report.
Thirty-six percent of over 100 very ill lymphoma patients appeared disease-free six months after a single treatment, according to results released by the treatment's maker, Kite Pharma of Santa Monica, Calif.
These patients had not responded to usual treatments and had no other options, Kite said Tuesday in a news release.
Overall, more than four out of five patients with the blood cancer saw their cancer reduced by more than half for at least part of the study, the company said.
"This seems extraordinary ... extremely encouraging," one cancer specialist, Dr. Roy Herbst, told the Associated Press.
But Herbst, who is chief of medical oncology at Yale Cancer Center in New Haven, Conn., said longer follow-up is needed to see if the benefit continues.
Still, he said, "This certainly is something I would want to have available." Side effects, which had been a concern, seemed manageable in this study, he said.
The therapy -- called CAR-T cell therapy -- enables the patient's own blood cells to kill the cancer cells.
Lymphoma is a general term for cancers that begin in the lymph system. The lymph system is part of the immune system, which helps the body fight disease.
Here's how the treatment works: A patient's blood is filtered so immune cells called T-cells can be altered to contain a cancer-fighting gene. The cells are returned to the patient intravenously, and the cancer-targeting cells then multiply in the patient's body.
The U.S. National Cancer Institute developed the gene approach and licensed it to Kite. Now, Kite and another pharmaceutical giant, Novartis AG, are competing to gain approval of the treatment, according to the AP.
Kite reportedly intends to seek U.S. Food and Drug Administration approval this spring and approval in Europe later this year. It could be the first gene therapy approved in the United States, the news report noted.
Although the therapy appears to benefit a significant number of patients, it is not risk-free. Researchers believe two patients died of treatment-related causes, the AP reported.
Other side effects included anemia or other blood problems that were treated, and neurological problems such as sleepiness, confusion, tremor or difficulty speaking, which typically lasted only a few days, the wire service reported.
Overall, however, the therapy seems safe, according to Dr. Steven Rosenberg, chief of surgery branch at the National Cancer Institute. He was not involved with the study.
"It's a safe treatment, certainly a lot safer than having progressive lymphoma," Rosenberg told the AP. He said he has a patient who was treated this way who is still in remission seven years later.
The cost of such treatment hasn't been reported yet, but immune system therapies tend to be very expensive.
The results are scheduled for presentation at the American Association for Cancer Research conference in April. Until published in a peer-reviewed medical journal, the data and conclusions should be considered preliminary.
Source: http://www.webmd.com/cancer/lymphoma/news/20170228/gene-therapy-shows-promise-for-aggressive-lymphoma
Saturday, May 16, 2026
Alendronate (Fosamax) - Osteoporosis - Patient guide - What to expect
Alendronate, widely known as Fosamax, is used in osteoporosis care to lower fracture risk and support long-term bone health. Patients often expect visible day-to-day changes, but treatment goals usually focus on maintaining bone strength over months and years. Best outcomes come from correct administration, fall prevention, and regular follow-up. Before clinic visits, patients can review alendronate treatment guidance and prepare questions. Useful monitoring includes dosing consistency, heartburn or swallowing discomfort, bone-density testing history, calcium and vitamin D intake, fall events, mobility confidence, and overall fracture-risk concerns. These records help clinicians tailor long-term prevention plans. Medication counseling should emphasize correct timing, upright posture after dosing, and avoiding food or other medicines too soon after administration. Patients should report persistent throat pain, severe heartburn, swallowing difficulty, jaw problems, or new severe bone pain early so clinicians can reassess safety. Supportive routines remain critical. Weight-bearing activity when appropriate, fall-prevention planning, hydration, adequate calcium and vitamin D intake, and smoking and alcohol risk reduction can improve bone-health stability. Urgent evaluation is needed for chest pain, severe swallowing pain, black stools, serious falls, sudden severe pain after minimal trauma, or other fracture concerns. Early escalation improves safety. Medication reconciliation at each appointment helps identify interacting products and broader bone-health risks. Patients should bring complete lists of prescriptions, over-the-counter products, and supplements. For broader osteoporosis-planning and fall-prevention tools, patients can use osteoporosis support resources and maintain written logs for clinic review. Reliable alendronate outcomes usually come from correct administration, lifestyle support, and timely reassessment when warning signs appear. Patients who keep weekly dosing, fall-risk, and symptom logs often identify treatment issues earlier, helping clinicians refine bone-health plans before fracture risk rises. Written administration reminders and urgent-warning checklists improve safety during long-term treatment. Routine bone-health follow-up supports durable fracture prevention. Consistent follow-up remains essential. Monitoring helps.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.